Answers are grounded in this paper and cite their sources.
Prospective study shows high acceptability and psychological safety in pregnant women undergoing CMV screening, highlighting its role in antenatal care.
Abstract Objective: The availability of valaciclovir to reduce fetal cytomegalovirus (CMV) transmission following maternal primary infection has renewed interest in antenatal screening. This study evaluated the acceptability, feasibility, and psychological impact of CMV prevention education combined with repeat serology at the end of the first trimester for seronegative pregnant women. Methods: In this prospective single-centre study, pregnant individuals who were CMV IgG negative before 12 weeks’ gestation were provided CMV prevention education and offered repeat serology at 12+0 to 13+6 weeks’ gestation. Participants completed CMV IgG and IgM testing, and online questionnaires at recruitment, 15-20 weeks' gestation, and 3-6 weeks postpartum. Acceptability and psychological impact were measured using a study-specific questionnaire, the State-Trait Anxiety Inventory, and the Decisional Regret Scale. Free text responses were analyzed with inductive content analysis. Results: Of 199 eligible participants, 137 were contactable, 84 received study information, and 66 (78%) consented. After 7 exclusions (6 due to miscarriage), 54/59 (92%) completed repeat CMV serology according to protocol. No CMV seroconversions were detected (0.0%; 95% CI: 0.0–6.6%). Satisfaction with the screening program was high (93%) and 96% would choose testing again. Compared to baseline, anxiety scores decreased significantly at 15-20 weeks’ gestation (mean difference 2.41, p=0.02) and in the postpartum period (mean difference 3.1, P = 0.04). No participants reported decisional regret. Four main categories emerged from the participant feedback: reassurance, improved CMV awareness, convenience, and ambivalence. Conclusion: CMV prevention education and repeat serology at the end of the first trimester was highly acceptable, feasible, and psychologically safe. These results support advancing to large scale implementation studies to incorporate CMV prevention strategies into practice.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: